(Q37320899)

19 August 2017

1 reference

title

Evolution of the health economics of cervical cancer vaccination (English)

1 reference

19 August 2017

main subject

cervix uterine cancer

1 reference

2

Maarten Postma

1 reference

19 August 2017

Nicole Ferko

1

1 reference

19 August 2017

Steve Gallivan

series ordinal

3

1 reference

19 August 2017

Denise Kruzikas

series ordinal

4

1 reference

19 August 2017

Michael Drummond

series ordinal

5

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 September 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

26 Suppl 5

1 reference

19 August 2017

page(s)

F3-15

1 reference

The global health burden of infection-associated cancers in the year 2002

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Review of the economic and quality-of-life burden of cervical human papillomavirus disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Cytological screening and management of abnormalities in prevention of cervical cancer: an overview with stochastic modelling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Withdrawing low risk women from cervical screening programmes: mathematical modelling study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Can papilloma virus testing be used to improve cervical cancer screening?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Cost-effectiveness of a potential vaccine for human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

The theoretical population-level impact of a prophylactic human papilloma virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Evaluating human papillomavirus vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Model for assessing human papillomavirus vaccination strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Cost-effectiveness analyses of human papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Multiparameter Calibration of a Natural History Model of Cervical Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.004

10.1016/J.VACCINE.2008.02.004

7 January 2021

Identifiers

DOI

1 reference

19 August 2017

1 reference